FEDERAL TRADE COMMISSION v. CEPHALON, INC.

CourtDistrict Court, E.D. Pennsylvania
DecidedOctober 13, 2021
Docket2:08-cv-02141
StatusUnknown

This text of FEDERAL TRADE COMMISSION v. CEPHALON, INC. (FEDERAL TRADE COMMISSION v. CEPHALON, INC.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
FEDERAL TRADE COMMISSION v. CEPHALON, INC., (E.D. Pa. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

FEDERAL TRADE COMMISSION, : : CIVIL ACTION Plaintiff, : : v. : : NO. 08-2141 CEPHALON, INC., et al. : : Defendants :

MEMORANDUM OPINION

Goldberg, J. October 13, 2021

This antitrust case emanates from several Hatch-Waxman “reverse payment” settlement agreements entered into between Defendant Cephalon, Inc. (“Cephalon”) and four generic drug companies.1 In February 2008, the Federal Trade Commission (“FTC”) filed a lawsuit against these entities claiming that they engaged in anticompetitive conduct in connection with the prescription drug Provigil®. After extensive litigation, the FTC and Defendants agreed to settle their dispute, and, on June 17, 2015, I entered a Stipulated Order for Permanent Injunction and Equitable Monetary Relief (the “Consent Decree”), which dismissed the FTC case with prejudice. Plaintiff-Intervenor the State of Louisiana (“Louisiana”) now moves to intervene in this action, pursuant to Federal Rule of Civil Procedure 24, in order to preserve its potential claim on the funds provided pursuant to the Stipulated Order. Defendants Cephalon, Teva Pharmaceuticals Industries, Ltd., Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. (collectively,

1 Barr Pharmaceuticals, Inc.; Mylan Laboratories, Inc. and Mylan Pharmaceuticals, Inc.; Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.; and Ranbaxy Laboratories, Ltd. and Ranbaxy Pharmaceuticals, Inc. Defendants”) all oppose that intervention. For the following reasons, I will deny Louisiana’s request to intervene. I. FACTUAL BACKGROUND A. The Federal Trade Commission Case The June 17, 2015 Consent Decree, in question, provided that Cephalon and its related entities were to pay $1.2 billion into a settlement fund (“Settlement Fund”) governed by the

Settlement Fund Disbursement Agreement, which was attached to the Consent Decree. Those monies were to be “held in trust to satisfy the amount of any settlement or judgment in a Related Case.” (Consent Decree, ECF No. 405, at 10.) “Related Case” is defined, in relevant part, as: [A]ny other government investigation or litigation that threatened in writing or filed that seeks to recover damages or equitable monetary relief based on alleged anticompetitive or other unlawful practices by the Cephalon Parties in connection with (1) the procurement, listing or enforcement of patents related to the drug Provigil®, (ii) FDA exclusivities related to the drug Provigil®; or (iii) settling litigation related to the drug Provigil®.

(Id. at 5–6.) The Consent Decree was originally set to expire ten years after the date of entry, and stated that the Court “retain[ed] jurisdiction of this matter for purposes of construction, modification, and enforcement of” the Consent Decree.” (Id. at 14.) Pursuant to the Settlement Fund Disbursement Agreement, “[t]he [FTC] shall close the Settlement Account if the entire Settlement Fund . . . has been fully disbursed or, in accordance with Paragraph 7, if the Commission pays any monies remaining in the Settlement Account . . . to the Treasurer of the United States.” (Settlement Fund Disbursement Agreement, ECF No. 405, ¶ 17.) Paragraph 7 mandates that “[t]he Cephalon Parties shall submit a list of Related Cases that have not been settled and for which a judgment has not been entered (‘Remaining Cases List’) on or up to 30 (thirty) days before the five-year anniversary of the entry of this Order, and each year thereafter, until, in the good faith belief of the Cephalon Parties, settlements have been reached, or final judgments entered, in the relevant Related Cases.” (Id. ¶ 7.) “If the Cephalon Parties do not submit a Remaining Cases List as provided in this paragraph, or the term of the Order has expired, any monies remaining in the Settlement Account, less reasonable administrative expenses, shall be paid to the Treasurer of the United States.” (Id.) On February 21, 2019, upon agreement of the parties, I entered a Revised Order for Permanent Injunction and Equitable Monetary Relief (“Revised Consent Decree). (ECF No. 410.)

Under this Revised Consent Decree, the original Settlement Fund Disbursement Agreement still governs, but the expiration date of original Consent Decree was extended through February 21, 2029. (Id. at 26.) Thus, I continue to retain jurisdiction for purposes of “construction, modification, and enforcement of the Revised Order.” (Id.) B. The Louisiana State Case On July 10, 2015, the State of Louisiana (“Louisiana”) filed suit against Cephalon (n/k/a Teva Pharmaceuticals, Inc.), Ranbaxy Pharmaceuticals, Inc., Mylan Laboratories, Inc., and Mylan Pharmaceuticals, Inc. (collectively, “State Defendants”) in the 19th Judicial District Court for the Parish of East Baton Rouge, Louisiana. Similar to the case before me, Louisiana alleged that the

State Defendants employed unlawful schemes designed to prevent or delay a less expensive generic version of Provigil® from entering the market. Louisiana also set forth multiple violations of Louisiana’s antitrust and consumer protection laws. Through two judgments entered on June 1, 2016 and December 8, 2016, the state court dismissed some, but not all of Louisiana’s claims. When Louisiana appealed those rulings, the Louisiana Court of Appeals dismissed the appeal for want of jurisdiction because some causes of action remained and because the trial court failed to include in its order the requisite language indicating that the December 8, 2016 judgment was a final judgment. State by and through Caldwell v. Teva Pharms. Indus., Ltd., 242 So.3d 597 (La. Ct. App. 2018). Louisiana does not report any further action on the case since February of 2018. Louisiana concedes that, pursuant to its reporting obligations in the Stipulated Order, Cephalon/Teva has reported Louisiana’s state court suit each year as a Related Case. II. DISCUSSION Federal Rule of Civil Procedure 24 provides, in pertinent part:

(a) Intervention of Right. On timely motion, the court must permit anyone to intervene who: . . . (2) claims an interest relating to the property or transaction that is the subject of the action, and is so situated that disposing of the action may as a practical matter impair or impede the movant’s ability to protect its interest, unless existing parties adequately represent that interest. . . .

(b) Permissive Intervention.

(1) In General. On timely, motion, the court may permit anyone to intervene who: . . . (B) has a claim or defense that shares with the main action a common question of law or fact.

Fed. R. Civ. P. 24. Louisiana currently seeks to intervene in the federal case before me both (1) as a matter of right under Federal Rule of Civil Procedure 24(a)(2) and (2) on a permissive basis under Federal Rule of Civil Procedure 24(b)(1)(B). Specifically, Louisiana asserts that it has a claim to the funds provided pursuant to the Revised Consent Decree and that it is the sole remaining “Related Case.” Defendants oppose Louisiana’s Motion on two grounds. First, they contend that the Motion is untimely, having been filed more than five years after the entry of the Consent Decree without any articulation of extraordinary circumstances. Second, they assert that Louisiana has failed to establish the elements necessary for either intervention as of right or permissive intervention. A.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Brody v. Spang
957 F.2d 1108 (Third Circuit, 1992)
Liberty Mutual Insurance Company v. Treesdale, Inc.
419 F.3d 216 (Third Circuit, 2005)
United States v. Gonzalez Becerra
784 F.3d 514 (Ninth Circuit, 2015)
State v. Teva Pharm. Indus., Ltd.
242 So. 3d 597 (Louisiana Court of Appeal, 2018)
Richard C. v. Houstoun
196 F.R.D. 288 (W.D. Pennsylvania, 1999)
In re Safeguard Scientifics
220 F.R.D. 43 (E.D. Pennsylvania, 2004)
Harris v. Pernsley
820 F.2d 592 (Third Circuit, 1987)

Cite This Page — Counsel Stack

Bluebook (online)
FEDERAL TRADE COMMISSION v. CEPHALON, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/federal-trade-commission-v-cephalon-inc-paed-2021.